{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:36:55Z","timestamp":1792291015107,"version":"4.4.0"},"reference-count":26,"publisher":"Portland Press Ltd.","issue":"2","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":836,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,4,30]]},"abstract":"<jats:p>We recently found that integrin \u03b1v\u03b23 binds to fibroblast growth factor (FGF)-\u03b1v\u03b231 (FGF1), and that the integrin-binding defective FGF1 mutant (Arg-50 to glutamic acid, R50E) is defective in signalling and antagonistic to FGF1 signalling. R50E suppressed angiogenesis and tumour growth, suggesting that R50E has potential as a therapeutic. However, FGF1 is unstable, and we had to express R50E in cancer cells for xenograft study, since injected R50E may rapidly disappear from circulation. We studied if we can develop antagonist of more stable FGF2. FGF2 is widely involved in important biological processes such as stem cell proliferation and angiogenesis. Previous studies found that FGF2 bound to \u03b1v\u03b23 and antagonists to \u03b1v\u03b23 suppressed FGF2-induced angiogenesis. However, it is unclear how FGF2 interacts with integrins. Here, we describe that substituting Lys-119\/Arg-120 and Lys-125 residues in the predicted integrin-binding interface of FGF2 to glutamic acid (the K119E\/R120E and K125E mutations) effectively reduced integrin binding to FGF2. These FGF2 mutants were defective in signalling functions (ERK1\/2 activation and DNA synthesis) in NIH3T3 cells. Notably they suppressed, FGF2 signalling induced by WT FGF2 in endothelial cells, suggesting that the FGF2 mutants are antagonists. The FGF2 mutants effectively suppressed tube formation in vitro, sprouting in aorta ring assays ex vivo and angiogenesis in vivo. The positions of amino acids critical for integrin binding are different between FGF1 and FGF2, suggesting that they do not interact with integrins in the same manner. The newly developed FGF2 mutants have potential as anti-angiogenic agents and useful tools for studying the role of integrins in FGF2 signalling.<\/jats:p>","DOI":"10.1042\/bsr20170173","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T20:30:28Z","timestamp":1489696228000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["The integrin-binding defective FGF2 mutants potently suppress FGF2 signalling and angiogenesis"],"prefix":"10.1042","volume":"37","author":[{"given":"Seiji","family":"Mori","sequence":"first","affiliation":[{"name":"Department of Medical Technology, Faculty of Health Sciences, Morinomiya University of Medical Sciences, 1-26-16 Nanko-kita, Suminoe, Osaka 559-8611, Japan"},{"name":"Department of Molecular Pathology, Division of Health Sciences, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Hatori","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology, Division of Health Sciences, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomasa","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology, Division of Health Sciences, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinosuke","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology, Division of Health Sciences, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Chieh","family":"Shih","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, California 95817, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, California 95817, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kit\u00a0S.","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, California 95817, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nariaki","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology, Division of Health Sciences, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology, Division of Health Sciences, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko\u00a0K.","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, California 95817, United States of America"},{"name":"Department of Dermatology, School of Medicine, University of California Davis, Sacramento, California 95817, United States of America"},{"name":"The PhD Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, 250 Wu-Hsing Street, Taipei 11031, Taiwan, R.O.C"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, California 95817, United States of America"},{"name":"Department of Dermatology, School of Medicine, University of California Davis, Sacramento, California 95817, United States of America"},{"name":"The PhD Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, 250 Wu-Hsing Street, Taipei 11031, Taiwan, R.O.C"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2017,4,10]]},"reference":[{"key":"2021111619102336200_B1","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1242\/dev.050146","article-title":"The role of FGF\/Erk signaling in pluripotent cells","volume":"137","author":"Lanner","year":"2010","journal-title":"Development"},{"key":"2021111619102336200_B2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.neuron.2011.08.002","article-title":"From cradle to grave: the multiple roles of fibroblast growth factors in neural development","volume":"71","author":"Guillemot","year":"2011","journal-title":"Neuron"},{"key":"2021111619102336200_B3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021111619102336200_B4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"key":"2021111619102336200_B5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/gb-2007-8-5-215","article-title":"The integrins","volume":"8","author":"Takada","year":"2007","journal-title":"Genome Biol."},{"key":"2021111619102336200_B6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.7512751","article-title":"Requirement of vascular integrin alpha v beta 3 for angiogenesis","volume":"264","author":"Brooks","year":"1994","journal-title":"Science"},{"key":"2021111619102336200_B7","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/hh2401.101084","article-title":"Integrin and growth factor receptor crosstalk","volume":"89","author":"Eliceiri","year":"2001","journal-title":"Circ. Res."},{"key":"2021111619102336200_B8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1530\/JOE-10-0377","article-title":"Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor","volume":"209","author":"Kim","year":"2011","journal-title":"J. Endocrinol."},{"key":"2021111619102336200_B9","first-page":"1117","article-title":"Plasticity of tumor cell invasion: governance by growth factors and cytokines","volume":"37","author":"Odenthal","year":"2016","journal-title":"Carcinogenesis"},{"key":"2021111619102336200_B10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"2021111619102336200_B11","doi-asserted-by":"crossref","first-page":"18066","DOI":"10.1074\/jbc.M801213200","article-title":"Direct binding of integrin \u03b1v\u03b23 to FGF1 plays a role in FGF1 signaling","volume":"283","author":"Mori","year":"2008","journal-title":"J. Biol. Chem."},{"key":"2021111619102336200_B12","first-page":"20","article-title":"Crosstalk between fibroblast growth factor (FGF) receptor and integrin through direct integrin binding to FGF and resulting integrin-FGF-FGFR ternary complex formation","volume":"1","author":"Mori","year":"2013","journal-title":"Med. Sci."},{"key":"2021111619102336200_B13","doi-asserted-by":"crossref","first-page":"e10273","DOI":"10.1371\/journal.pone.0010273","article-title":"A novel fibroblast growth factor-1 (FGF1) mutant that acts as an FGF antagonist","volume":"5","author":"Yamaji","year":"2010","journal-title":"PLoS ONE"},{"key":"2021111619102336200_B14","doi-asserted-by":"crossref","first-page":"e57927","DOI":"10.1371\/journal.pone.0057927","article-title":"A dominant-negative FGF1 mutant (the R50E Mutant) suppresses tumorigenesis and angiogenesis","volume":"8","author":"Mori","year":"2013","journal-title":"PLoS ONE"},{"key":"2021111619102336200_B15","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1091\/mbc.8.12.2449","article-title":"Alphavbeta3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells","volume":"8","author":"Rusnati","year":"1997","journal-title":"Mol. Biol. Cell"},{"key":"2021111619102336200_B16","doi-asserted-by":"crossref","first-page":"26107","DOI":"10.1074\/jbc.M804835200","article-title":"Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in an integrin-dependent manner","volume":"283","author":"Saegusa","year":"2008","journal-title":"J. Biol. Chem."},{"key":"2021111619102336200_B17","doi-asserted-by":"crossref","first-page":"7937","DOI":"10.1074\/jbc.M513035200","article-title":"Non-cytotoxic cobra cardiotoxin A5 binds to alpha(v)beta3 integrin and inhibits bone resorption. Identification of cardiotoxins as non-RGD integrin-binding proteins of the Ly-6 family","volume":"281","author":"Wu","year":"2006","journal-title":"J. Biol. Chem."},{"key":"2021111619102336200_B18","doi-asserted-by":"crossref","first-page":"19593","DOI":"10.1074\/jbc.M113.470872","article-title":"An integrin binding-defective mutant of insulin-like growth factor-1 (R36E\/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R","volume":"288","author":"Fujita","year":"2013","journal-title":"J. Biol. Chem."},{"key":"2021111619102336200_B19","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.4049\/jimmunol.1200889","article-title":"Integrins \u03b1v\u03b23 and \u03b14\u03b21 act as coreceptors for fractalkine, and the integrin-binding defective mutant of fractalkine is an antagonist of CX3CR1","volume":"189","author":"Fujita","year":"2012","journal-title":"J. Immunol."},{"key":"2021111619102336200_B20","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1016\/S0021-9258(18)61504-2","article-title":"The VLA protein family. Characterization of five distinct cell surface heterodimers each with a common 130,000 molecular weight beta subunit","volume":"262","author":"Hemler","year":"1987","journal-title":"J. Biol. Chem."},{"key":"2021111619102336200_B21","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1083\/jcb.140.5.1255","article-title":"Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis","volume":"140","author":"Eliceiri","year":"1998","journal-title":"J. Cell Biol."},{"key":"2021111619102336200_B22","doi-asserted-by":"crossref","first-page":"R540","DOI":"10.1016\/j.cub.2006.06.038","article-title":"Cell cycle: sustained ERK signalling represses the inhibitors","volume":"16","author":"Sharrocks","year":"2006","journal-title":"Curr. Biol."},{"key":"2021111619102336200_B23","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/stem.1021","article-title":"Thermal stability of fibroblast growth factor protein is a determinant factor in regulating self-renewal, differentiation, and reprogramming in human pluripotent stem cells","volume":"30","author":"Chen","year":"2012","journal-title":"Stem Cells"},{"key":"2021111619102336200_B24","doi-asserted-by":"crossref","first-page":"15292","DOI":"10.1074\/jbc.271.25.15292","article-title":"Receptor specificity of the fibroblast growth factor family","volume":"271","author":"Ornitz","year":"1996","journal-title":"J. Biol. Chem."},{"key":"2021111619102336200_B25","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/0092-8674(94)90007-8","article-title":"Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels","volume":"79","author":"Brooks","year":"1994","journal-title":"Cell"},{"key":"2021111619102336200_B26","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1126\/science.270.5241.1500","article-title":"Definition of two angiogenic pathways by distinct alpha v integrins","volume":"270","author":"Friedlander","year":"1995","journal-title":"Science"}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20170173\/519543\/bsr-2017-0173-t.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20170173\/519543\/bsr-2017-0173-t.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T15:01:55Z","timestamp":1637074915000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/37\/2\/BSR20170173\/83421\/The-integrin-binding-defective-FGF2-mutants"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,10]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4,30]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20170173","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1007\/s40203-025-00495-2","asserted-by":"object"}]},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,10]]},"article-number":"BSR20170173"}}